Literature DB >> 18426493

Cannabinoid receptors: where they are and what they do.

K Mackie1.   

Abstract

The endocannabinoid system consists of the endogenous cannabinoids (endocannabinoids), cannabinoid receptors and the enzymes that synthesise and degrade endocannabinoids. Many of the effects of cannabinoids and endocannabinoids are mediated by two G protein-coupled receptors (GPCRs), CB(1) and CB(2), although additional receptors may be involved. CB(1) receptors are present in very high levels in several brain regions and in lower amounts in a more widespread fashion. These receptors mediate many of the psychoactive effects of cannabinoids. CB(2) receptors have a more restricted distribution, being found in a number of immune cells and in a few neurones. Both CB(1) and CB(2) couple primarily to inhibitory G proteins and are subject to the same pharmacological influences as other GPCRs. Thus, partial agonism, functional selectivity and inverse agonism all play important roles in determining the cellular response to specific cannabinoid receptor ligands.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18426493     DOI: 10.1111/j.1365-2826.2008.01671.x

Source DB:  PubMed          Journal:  J Neuroendocrinol        ISSN: 0953-8194            Impact factor:   3.627


  154 in total

1.  Crosstalk between the brain and bone.

Authors:  Laura Masi
Journal:  Clin Cases Miner Bone Metab       Date:  2012-05-29

2.  Chromenopyrazoles: non-psychoactive and selective CB₁ cannabinoid agonists with peripheral antinociceptive properties.

Authors:  Jose Cumella; Laura Hernández-Folgado; Rocio Girón; Eva Sánchez; Paula Morales; Dow P Hurst; Maria Gómez-Cañas; Maria Gómez-Ruiz; Diana C G A Pinto; Pilar Goya; Patricia H Reggio; María Isabel Martin; Javier Fernández-Ruiz; Artur M S Silva; Nadine Jagerovic
Journal:  ChemMedChem       Date:  2012-02-02       Impact factor: 3.466

3.  AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.

Authors:  Kathryn A Seely; Lisa K Brents; Lirit N Franks; Maheswari Rajasekaran; Sarah M Zimmerman; William E Fantegrossi; Paul L Prather
Journal:  Neuropharmacology       Date:  2012-07-04       Impact factor: 5.250

4.  Sativex(®) and clinical-neurophysiological measures of spasticity in progressive multiple sclerosis.

Authors:  Letizia Leocani; Arturo Nuara; Elise Houdayer; Irene Schiavetti; Ubaldo Del Carro; Stefano Amadio; Laura Straffi; Paolo Rossi; Vittorio Martinelli; Carlos Vila; Maria Pia Sormani; Giancarlo Comi
Journal:  J Neurol       Date:  2015-08-20       Impact factor: 4.849

5.  Exposure of Adolescent Mice to Delta-9-Tetrahydrocannabinol Induces Long-Lasting Modulation of Pro- and Anti-Inflammatory Cytokines in Hypothalamus and Hippocampus Similar to that Observed for Peripheral Macrophages.

Authors:  Sarah Moretti; Silvia Franchi; Mara Castelli; Giada Amodeo; Lorenzo Somaini; Alberto Panerai; Paola Sacerdote
Journal:  J Neuroimmune Pharmacol       Date:  2015-02-10       Impact factor: 4.147

6.  Anandamide oxidation by wild-type and polymorphically expressed CYP2B6 and CYP2D6.

Authors:  Chitra Sridar; Natasha T Snider; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2011-02-02       Impact factor: 3.922

7.  Emotion regulation deficits in regular marijuana users.

Authors:  Kaeli Zimmermann; Christina Walz; Raissa T Derckx; Keith M Kendrick; Bernd Weber; Bruce Dore; Kevin N Ochsner; René Hurlemann; Benjamin Becker
Journal:  Hum Brain Mapp       Date:  2017-05-31       Impact factor: 5.038

8.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

9.  Endocannabinoid Virodhamine Is an Endogenous Inhibitor of Human Cardiovascular CYP2J2 Epoxygenase.

Authors:  Lauren N Carnevale; Andres S Arango; William R Arnold; Emad Tajkhorshid; Aditi Das
Journal:  Biochemistry       Date:  2018-11-06       Impact factor: 3.162

10.  Predicting the molecular interactions of CRIP1a-cannabinoid 1 receptor with integrated molecular modeling approaches.

Authors:  Mostafa H Ahmed; Glen E Kellogg; Dana E Selley; Martin K Safo; Yan Zhang
Journal:  Bioorg Med Chem Lett       Date:  2014-01-08       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.